Works by Hasler-Strub, Ursula

Results: 4
    1

    A multicenter phase II trial of anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple negative breast cancer.

    Published in:
    Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-30950-z
    By:
    • Mamot, Christoph;
    • Wicki, Andreas;
    • Hasler-Strub, Ursula;
    • Riniker, Salome;
    • Li, Qiyu;
    • Holer, Lisa;
    • Bärtschi, Daniela;
    • Zaman, Khalil;
    • von Moos, Roger;
    • Dedes, Konstantin J.;
    • Boos, Laura A.;
    • Novak, Urban;
    • Bodmer, Alexandre;
    • Ritschard, Reto;
    • Obermann, Ellen C.;
    • Tzankov, Alexandar;
    • Ackermann, Christoph;
    • Membrez-Antonioli, Véronique;
    • Zürrer-Härdi, Ursina;
    • Caspar, Clemens B.
    Publication type:
    Article
    2

    SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial.

    Published in:
    2016
    By:
    • Rochlitz, Christoph;
    • Bigler, Martin;
    • von Moos, Roger;
    • Bernhard, Jürg;
    • Matter-Walstra, Klazien;
    • Wicki, Andreas;
    • Zaman, Khalil;
    • Anchisi, Sandro;
    • Küng, Marc;
    • Na, Kyung-Jae;
    • Bärtschi, Daniela;
    • Borner, Markus;
    • Rordorf, Tamara;
    • Rauch, Daniel;
    • Müller, Andreas;
    • Ruhstaller, Thomas;
    • Vetter, Marcus;
    • Trojan, Andreas;
    • Hasler-Strub, Ursula;
    • Cathomas, Richard
    Publication type:
    journal article
    3

    SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2- negative advanced stage breast cancer - a multicenter, randomized phase III trial

    Published in:
    BMC Cancer, 2016, v. 16, p. 1, doi. 10.1186/s12885-016-2823-y
    By:
    • Rochlitz, Christoph;
    • Bigler, Martin;
    • von Moos, Roger;
    • Bernhard, Jürg;
    • Matter-Walstra, Klazien;
    • Wicki, Andreas;
    • Zaman, Khalil;
    • Anchisi, Sandro;
    • Küng, Marc;
    • Kyung-Jae Na;
    • Bärtschi, Daniela;
    • Borner, Markus;
    • Rordorf, Tamara;
    • Rauch, Daniel;
    • Müller, Andreas;
    • Ruhstaller, Thomas;
    • Vetter, Marcus;
    • Trojan, Andreas;
    • Hasler-Strub, Ursula;
    • Cathomas, Richard
    Publication type:
    Article
    4

    DOMENICA study (GINECO-EN105b/ENGO-Ten13): randomized phase III trial in MMR deficient (MMRd) endometrial cancer (EC) patients comparing chemotherapy (CT) alone versus dostarlimab in first line advanced/metastatic setting (APGOT-EN1).

    Published in:
    Journal of Gynecologic Oncology, 2024, v. 35, p. 19, doi. 10.3802/jgo.2024.35.S2.P1
    By:
    • Chel Hun Choi;
    • Ray-Coquard, Isabelle;
    • Rubio, Maria Jesus;
    • Paoletti, Xavier;
    • Hudson, Emma;
    • Lorusso, Domenica;
    • Hasler-Strub, Ursula;
    • Vardar, Mehmet Ali;
    • Lheureux, Stéphanie;
    • Van Gorp, Toon;
    • Shao Peng Tan, David;
    • Trillsch, Fabian;
    • Eberst, Lauriane;
    • Lescure, Céline;
    • Hardy-Bessard, Anne-Claire;
    • Chaix, Marie;
    • Byoung-Gie Kim;
    • JaeWeon Kim;
    • JeongYeol Park;
    • Jung-Yun Lee
    Publication type:
    Article